Physician profile
Vikesh Khanijow
NPI 1962768531
$9,491.08
in general payments reported to CMS, 2019-2025
34 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $700 · 2021: $1,614 · 2022: $1,392 · 2023: $1,410 · 2024: $1,930 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,945 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.24 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,606.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,117.18 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $734.47 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $620.60 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $498.17 | 2019-2025 | |
| Celgene Corporation | $430.06 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $241.12 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $224.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $205.28 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $186.45 | 2024-2025 | Voquezna |
| Genzyme Corporation | $172.75 | 2022-2025 | |
| Allergan, INC. | $158.63 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $156.94 | 2019-2023 | Linzess |
| Lilly USA, LLC | $154.82 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $118.12 | 2020-2025 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $117.89 | 2022-2025 | Ibsrela |
| Evoke Pharma, INC. | $112.22 | 2020-2023 | Gimoti |
| Celltrion USA INC. | $81.62 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $78.66 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $65.19 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $51.24 | 2021-2024 | Sutab, Suflave |
| Ucb, INC. | $50.62 | 2019-2020 | |
| Medtronic, INC. | $42.03 | 2022 | |
| Vivus LLC | $40.86 | 2022-2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $28.96 | 2025 | Iqirvo |
| Shield Therapeutics INC | $27.29 | 2025 | |
| Merck Sharp & Dohme LLC | $25.70 | 2021 | |
| Axonics, INC. | $25.37 | 2024 | Axonics |
| Redhill Biopharma INC. | $25.11 | 2021 | |
| Teleflex LLC | $25.07 | 2025 | Solesta |
| Ferring Pharmaceuticals INC. | $23.28 | 2020-2022 | |
| Shire North American Group INC | $17.67 | 2019 | |
| Lucid Diagnostics INC. | $15.80 | 2024 | |
| Ethicon US, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikesh Khanijow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.